DISCOUNT OPTIONSSCHEIN - MODERNA | Market Closed - Deutsche Boerse AG 18:55:12 23/05/2024 BST | ||
| 0.75 EUR | -14.77% |
|
| Current month | -77.06% | ||
| 1 month | -77.54% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 23/05/24 | 0.75 | -14.77% |
| 22/05/24 | 0.88 | -50.56% |
| 21/05/24 | 1.78 | -0.56% |
| 20/05/24 | 1.79 | -22.84% |
| 17/05/24 | 2.32 | -3.73% |
Delayed Quote Deutsche Boerse AG
Last update May 23, 2024 at 06:55 pm
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| WKN | VU1SXL |
| ISIN | DE000VU1SXL7 |
| Date issued | 05/01/2023 |
| Strike | 160 $ |
| Maturity | 21/06/2024 (29 Days) |
| Parity | 10 : 1 |
| Emission price | 1.51 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.54 € |
|---|---|
| Lowest since issue | 0.75 € |
| Spread | 0.01 € |
| Spread % | 1.39% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
164
USD
Average target price
138.5
USD
Spread / Average Target
-15.55%
- Stock Market
- Certificates
- Certificat
